G

Genfit SA
PAR:GNFT

Watchlist Manager
Genfit SA
PAR:GNFT
Watchlist
Price: 3.455 EUR -0.14%
Market Cap: 172.3m EUR
Have any thoughts about
Genfit SA?
Write Note

Genfit SA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genfit SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
G
Genfit SA
PAR:GNFT
Revenue
€84m
CAGR 3-Years
151%
CAGR 5-Years
61%
CAGR 10-Years
29%
Valneva SE
PAR:VLA
Revenue
€229.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Revenue
€24.9m
CAGR 3-Years
-10%
CAGR 5-Years
-26%
CAGR 10-Years
11%
Inventiva SA
PAR:IVA
Revenue
€15.6m
CAGR 3-Years
255%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Revenue
€144.2m
CAGR 3-Years
-13%
CAGR 5-Years
21%
CAGR 10-Years
17%
OSE Immunotherapeutics SA
PAR:OSE
Revenue
€83.4m
CAGR 3-Years
83%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

Genfit SA
Glance View

Market Cap
172.2m EUR
Industry
Biotechnology

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

GNFT Intrinsic Value
28.986 EUR
Undervaluation 88%
Intrinsic Value
Price
G

See Also

What is Genfit SA's Revenue?
Revenue
84m EUR

Based on the financial report for Jun 30, 2024, Genfit SA's Revenue amounts to 84m EUR.

What is Genfit SA's Revenue growth rate?
Revenue CAGR 10Y
29%

Over the last year, the Revenue growth was 182%. The average annual Revenue growth rates for Genfit SA have been 151% over the past three years , 61% over the past five years , and 29% over the past ten years .

Back to Top